References
- Finkbeiner, P.; Hehn, J. P.; Gnamm, C. Phosphine Oxides from a Medicinal Chemist’s Perspective: Physicochemical and in Vitro Parameters Relevant for Drug Discovery. J. Med. Chem. 2020, 63, 7081–7107.
- Markham, A. Brigatinib: First Global Approval. Drugs 2017, 77, 1131–1135. DOI: 10.1007/s40265-017-0776-3.
- Rivera, V. M.; Squillace, R. M.; Miller, D.; Berk, L.; Wardwell, S. D.; Ning, Y.; Pollock, R.; Narasimhan, N. I.; Iuliucci, J. D.; Wang, F.; Clackson, T. Ridaforolimus (AP23573; MK-8669), A Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens. Mol. Cancer Ther. 2011, 10, 1059–1071. DOI: 10.1158/1535-7163.MCT-10-0792.
- Kendall, A. J.; Seidenkranz, D. T.; Tyler, D. R. Improved Synthetic Route to Heteroleptic Alkylphosphine Oxides. Organometallics 2017, 36, 2412–2417. DOI: 10.1021/acs.organomet.7b00304.
- Volkholz, M.; Stelzer, O.; Schmutzler, R. Darstellung Und Reaktionen Des Dimethyl-Phosphinigsäuretrimethylsilylesters, Me2P-OSiMe3. Chem. Ber. 1978, 111, 890–900. DOI: 10.1002/cber.19781110309.
- Hagens, W.; Bos, H. J. T.; Arens, J. F. Dialkyl(Methylthioethynyl)Phosphine Oxides; Synthesis and Reactions. Recl. Trav. Chim. Pays-Bas. 1973, 92, 762–774. DOI: 10.1002/recl.19730920711.
- Dahl, O.; Henriksen, U.; Trebbien, C.; Carlberg, G. E.; Sterner, O.; Wickberg, B. Methyl(Cyanomethyl)Phosphines. Synthesis and Nucleophilic Reactivity. Acta Chem. Scand. 1983, 37b, 639–642. DOI: 10.3891/acta.chem.scand.37b-0639.